Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989 Nov;60(5):767-9.
doi: 10.1038/bjc.1989.356.

Cisplatin/carboplatin cross-resistance in ovarian cancer

M E Gore  1 , I Fryatt, E Wiltshaw, T Dawson, B A Robinson, A H Calvert
Affiliations
Free PMC article

Cisplatin/carboplatin cross-resistance in ovarian cancer

M E Gore et al. Br J Cancer. 1989 Nov.
Free PMC article

Abstract

Forty-six patients who were treated with cisplatin or carboplatin for ovarian cancer developed resistant disease (no change in measurable disease or progressive disease) and 'crossed over' to the other platinum compound. Three patients (6.5%) responded to this second treatment but these patients had no survival advantage compared to the non-responders. One responder had progressive disease on cisplatin before crossing over to carboplatin.

PubMed Disclaimer

References

    1. Cancer Res. 1985 Jan;45(1):86-90 - PubMed
    1. Cancer Treat Rep. 1983 Nov;67(11):997-1000 - PubMed
    1. Cancer Treat Rev. 1985 Sep;12 Suppl A:67-71 - PubMed
    1. Cancer Res. 1986 Apr;46(4 Pt 2):1972-9 - PubMed
    1. J Clin Oncol. 1986 May;4(5):722-9 - PubMed